Mesenchymal Stromal (Stem) Cell Therapy Fails to Improve Outcomes in Experimental Severe Influenza

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Darwish, Ilyse ^a,b   Banner, David ^c   Mubareka, Samira ^d   Kim, Hani ^b   Besla, Rickvinder ^a   Kelvin, David J ^c   Kain, Kevin C ^a,b,c   Liles, W Conrad ^a,b,c,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN M; MONOCYTE CHEMOTACTIC PROTEIN 1; OSELTAMIVIR; PROTEIN; RANTES;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; HUMAN CELL; INFLUENZA; LUNG LAVAGE; LUNG PARENCHYMA; MACROPHAGE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MONOCYTE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PNEUMONIA; PROTEIN BLOOD LEVEL; SURVIVAL; TREATMENT FAILURE; WEIGHT REDUCTION;

ANIMALS; ANTIVIRAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CELL- AND TISSUE-BASED THERAPY; DISEASE MODELS, ANIMAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMONIA; TREATMENT FAILURE;

EID: 84881562206     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071761     Document Type: Article

References (56)

1. World Health Organization. Available: http://www.who.int/mediacentre/factsheets/2003/fs211/en/. Accessed: 2012 Nov 3.
2. Dawson TC, Beck MA, Kuziel WA, Henderson F, Maeda N, (2000) Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol 156: 1951-1959.
3. Carey MA, Bradbury JA, Seubert JM, Langenbach R, Zeldin DC, et al. (2005) Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J Immunol 175: 6878-6884.
4. Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, et al. (2007) Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445: 319-323.
5. Perrone LA, Plowden JK, García-Sastre A, Katz JM, Tumpey TM, (2008) H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog 4: e1000115.
6. Perrone L, Szretter K, Katz J, Mizgerd J, Tumpey T, (2010) Mice lacking both TNF and IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus. J Infect Dis 202: 1161-1170.
7. Lin KL, Sweeney S, Kang BD, Ramsburg E, Gunn MD, (2011) CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection. J Immunol 186: 508-515.
8. Peiris J, Yu WC, Leung CW, Cheung CY, Ng WF, et al. (2004) Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363: 617-619.
9. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJD, et al. (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12: 1203-1207.
10. To K, Chan PK, Chan K, Lee WK, Lam WY, et al. (2001) Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol 63: 242-246.
11. Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, et al. (2004) Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350: 1179-1188.
12. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, et al. (2005) Avian Influenza A (H5N1) Infection in humans. N Engl J Med 353: 1374-1385.
13. Abdel-Ghafar A-N, Chotpitayasunondh T, Gao Z, Hayden FG, Hien ND, et al. (2008) Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358: 261-273.
14. Gill JR, Sheng Z-M, Ely SF, Guinee Jr DG, Beasley MB, et al. (2010) Pulmonary pathological findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med 134: 235-253.
15. Ware LB, Matthay MA, (2000) The acute respiratory distress syndrome. N Engl J Med 342: 1334-1349.
16. Bernard GR, (2005) Acute respiratory distress syndrome: A historical perspective. Am J Respir Crit Care Med 172: 798-806.
17. World Health Organization. Available: http://www.who.int/wer/2011/wer8610.pdf. Accessed: 2012 Nov 7.
18. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, et al. (2008) Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52: 3284-3292.
19. Murphy BR, Baron S, Chalhub EG, Uhlendorf CP, Chanock RM, (1973) Temperature-sensitive mutants of influenza virus. IV. Induction of interferon in the nasopharynx by wild-type and a temperature- sensitive recombinant virus. J Infect Dis 128: 488-493.
20. Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, et al. (2003) Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 51: 123-129.
21. Kandun IN, Tresnaningsih E, Purba WH, Lee V, Samaan G, et al. (2008) Factors associated with case fatality of human H5N1 virus infections in Indonesia: A case series. Lancet 372: 744-749.
22. Jain S, Kamimoto L, Bramley AM, Shmitz AM, Benoit SR, et al. (2009) Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 361: 1935-1944.
23. To KKW, Hung IFN, Li IWS, Lee K-L, Koo C-K, et al. (2010) Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 50: 850-859.
24. De Jong MD, Thanh TT, Khanh TH, Hien VM, Smith GJD, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-2672.
25. Rojas M, Xu J, Woods CR, Mora AL, Spears W, et al. (2005) Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 33: 145-152.
26. Mei SH, McCarter SD, Deng Y, Parker CH, Liles CW, et al. (2007) Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 4: 1525-1537.
27. Xu J, Qu J, Cao L, Sai Y, Chen C, et al. (2008) Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. J Pathol 214: 472-481.
28. Gupta N, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan X, et al. (2012) Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherechia coli pneumonia. Thorax 67: 533-539.
29. Ortiz LA, Gambelli F, McBride C, (2003) Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 100: 8407-8411.
30. Xu J, Woods CR, Mora AL, Joodi R, Brigham KL, et al. (2007) Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol 293: L131-141.
31. Gupta N, Su X, Popov B, Lee JW, Serikov V, et al. (2007) Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 179: 1855-1863.
32. Lee JW, Fang X, Gupta N, Serikov V, Matthay MA, (2009) Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA 106: 16357-16362.
33. Prockop DJ, (1997) Marrow stromal cells as stem cells for nonhematopoetic tissue. Science 276: 71-74.
34. Bianco P, Robey PG, (2000) Marrow stromal stem cells. J Clin Invest 105: 1663-1668.
35. Mei SHJ, Haitsma JJ, Dos Santos CC, Deng Y, Lai PFH, et al. (2010) Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 182: 1047-1057.
36. Dos Santos CC, Murthy S, Hu P, Shan Y, Haitsma JJ, et al. (2012) Network analysis of transcriptional responses induced by mesenchymal stem cell treatment of experimental sepsis. Am J Pathol 181: 1681-1692.
37. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytother 8: 315-317.
38. Danchuk S, Ylostalo J, Hossain F, Sorge R, Ramsey A, et al. (2011) Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6. Stem Cell Res Ther 2: 27.
39. Yagi H, Soto-Gutierrez A, Navarro-Alvarez N, Nahmias Y, Goldwasser Y, et al. (2010) Reactive Bone Marrow Stromal Cells Attenuate Systemic Inflammation via sTNFR1. Mol Ther 18: 1857-1864.
40. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, et al. (2009) Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5: 54-63.
41. Ren G, Su J, Zhang L, Zhao X, Ling W, et al. (2009) Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27: 1954-1962.
42. Djouad F, Fritz V, Apparailly F, Louis-Plence P, Bony C, et al. (2005) Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor α in collagen-induced arthritis. Arthritis Rheum 52: 1595-1603.
43. Sudres M, Norol F, Trenado A, Gregoire S, Charlotte F, et al. (2006) Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft vs host disease in mice. J Immunol 176: 7761-7767.
44. Inoue S, Popp FC, Koehl GE, (2006) Immunomodulatory effects of MSCs in a rat organ transplant model. Transplantation 81: 1589-1596.
45. Chan JL, Tang KC, Patel AP, Bonilla LM, Pierobon N, et al. (2006) Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-γ. Blood 107: 4817-4824.
46. Nemeth K, Leelahavanichkul A, Yuen PST, Mayer B, Parmelee A, et al. (2009) Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15: 42-49.
47. McCullers JA, (2006) Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 19: 571-582.
48. Khatri M, Saif YM, (2013) Influenza virus infects bone marrow mesenchymal stromal cells in vitro: implications for bone marrow transplantation. Cell Transplant 22: 461-468.
49. Liotta F, Angeli R, Cosmi L, Filì L, Manuelli C, et al. (2008) Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 26: 279-289.
50. Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR, (2006) Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J Virol 80: 5059-5064.
51. Diebold SS, Kaisho T, Hemmi H, Akira S, Sousa CR, et al. (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531.
52. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, et al. (2004) Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 101: 5598-5603.
53. Cho HH, Bae YC, Jung JS, (2006) Role of Toll-Like Receptors on Human Adipose-Derived Stromal Cells. Stem Cells 24: 2744-2752.
54. Pevsner-Fisher M, Morad V, Cohen-Sfady M, Rousso-Noori L, Zanin-Zhorov A, et al. (2007) Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109: 1422-1432.
55. Mindrescu C, Le J, Wisniewski HG, Vilcek J, (2005) Up-regulation of cyclooxygenase-2 expression by TSG-6 protein in macrophage cell line. Biochem Biophys Res Commun 330: 737-745.
56. Lee S, Cheung C, Nicholls J, Hui KPY, Leung CYH, et al. (2008) Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: A mechanism for the pathogenesis of avian influenza H5N1 infection. J Infect Dis 198: 525-535.